The earnings call presented a mixed picture with strong financial health and promising Phase 2a study results highlighting the potential of Nimazumab in combination with semaglutide. However, increased R&D expenses, a larger net loss, concerns about monotherapy efficacy, and limited study enrollment were notable challenges.

Company Guidance

In the Skye Bioscience, Inc. third-quarter 2025 earnings call, the company provided detailed guidance on its financial and clinical development milestones. Key financial highlights included ending the quarter with $35.3 million in cash and equivalents, with expectations to fund operations into 2027. R&D expenses increased to $9.4 million from $4.9 million in the previous year due to ongoing clinical trials, including those for Nolasimab and Nimazumab. Notably, the company reported a net loss of $12.8 million, attributed partly to non-cash share-based compensation expenses. Clinical updates focused on the promising results from the Phase 2a CBEYOND study, showing a 3% additional weight loss with Nimazumab plus semaglutide compared to semaglutide alone, with a significant p-value of 0.0372. The study also demonstrated improvements in lean to fat mass ratio and reduced waist circumference, with retention strong in the extension study. The company is advancing Nimazumab's dose concentration strategy and plans to evaluate higher doses in future studies, keeping scalability and patient convenience in focus.

Strong Financial Position

Skye Bioscience ended the third quarter with cash and cash equivalents totaling $35.3 million, which is expected to fund operations and key clinical milestones into 2027.

Successful Phase 2a Study Results

The Phase 2a CBEYOND study showed synergistic efficacy with Nimazumab plus semaglutide, achieving approximately 3% additional weight loss at 26 weeks with a p-value of 0.0372, nearly a 30% improvement.

Positive Safety Profile

Nimazumab demonstrated a positive safety signal with no neuropsychiatric signals or additive GI burden.

Durability of Weight Loss

In a 12-week post-treatment follow-up, Nimazumab plus semaglutide showed significantly less weight regain (18% vs. 50% in semaglutide alone), with a p-value of 0.006.

Encouraging KOL Feedback

Key opinion leaders have responded positively to the combination data, emphasizing the potential for dosing holidays without significant weight regain.

Skye Bioscience (SKYE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SKYE Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 19, 2026	2025 (Q4)	-0.30 / -	-0.24	―	―	―
Nov 10, 2025	2025 (Q3)	-0.31 / -0.32	-0.1	-220.00% (-0.22)	―
Aug 07, 2025	2025 (Q2)	-0.32 / -0.44	-0.2	-120.00% (-0.24)
May 08, 2025	2025 (Q1)	-0.29 / -0.28	-0.18	-55.56% (-0.10)	―
Mar 20, 2025	2024 (Q4)	-0.28 / -0.24	-0.36	33.33% (+0.12)	―
Nov 07, 2024	2024 (Q3)	-0.25 / -0.10	-3.17	96.85% (+3.07)	―
Aug 09, 2024	2024 (Q2)	-0.20 / -0.20	-0.8	75.00% (+0.60)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SKYE Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 10, 2025	$1.42	$1.46	+2.82%
Aug 07, 2025	$3.55	$3.52	-0.85%
May 08, 2025	$1.79	$1.81	+1.12%
Mar 20, 2025	$1.89	$2.25	+19.05%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Skye Bioscience (SKYE) report earnings?

Skye Bioscience (SKYE) is schdueled to report earning on Mar 19, 2026, After Close (Confirmed).

What is Skye Bioscience (SKYE) earnings time?

Skye Bioscience (SKYE) earnings time is at Mar 19, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is SKYE EPS forecast?

SKYE EPS forecast for the fiscal quarter 2025 (Q4) is -0.3.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing